Interaction Between NOS3 and HMOX1 on Antihypertensive Drug Responsiveness in Preeclampsia

• Autor(a) principal: Sandrim, Valeria Cristina [UNESP]
• Data de Publicação: 2020
• Outros Autores: Luizon, Marcelo Rizzatti, Pilan, Eliane [UNESP], Caldeira-Dias, Mayara [UNESP], Coeli-Lacchini, Fernanda Borchers, Kors, Georgia [UNESP], Berndt, Iuly [UNESP], Lacchini, Riccardo, Cavalli, Ricardo Carvalho
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1055/s-0040-1712484; http://hdl.handle.net/11449/209512
• topic: preeclampsia; polymorphism; antioxidant; nitric oxide

Objective We examined the interaction of polymorphisms in the genes heme oxygenase-1 (HMOX1) and nitric oxide synthase (NOS3) in patients with preeclampsia (PE) as well as the responsiveness to methyldopa and to total antihypertensive therapy. Methods The genes HMOX1 (rs2071746, A/T) and NOS3 (rs1799983, G/T) were genotyped using TaqMan allele discrimination assays (Applied Biosystems, Foster City, CA, USA), and the levels of enzyme heme oxygenase-1 (HO-1) were measured using enzyme-linked immunosorbent assay (ELISA). Results We found interactions between genotypes of the HMOX-1 and NOS3 genes and responsiveness tomethyldopa and that PE genotyped as AT presents lower levels of protein HO-1 compared with AA. Conclusion We found interactions between the HMOX-1 and NOS3 genes and responsiveness to methyldopa and that the HMOX1 polymorphism affects the levels of enzyme HO-1 in responsiveness to methyldopa and to total antihypertensive therapy. These data suggest impact of the combination of these two polymorphisms on antihypertensive responsiveness in PE.